Skip to main content

Table 2 Subgroup analysis and meta-regression of the association between CD9 expression and overall survival in cancer patients

From: Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis

Subgroup Number of studies Number of patients Pooled HR (95% CI) p value Heterogeneity Meta-regression
I2 (%) p value p value
Cancer type        0.298
 Breast cancer 2 252 0.27 (0.12–0.63) 0.002 0.0 0.761  
 Digestive system cancer 4 410 0.39 (0.24–0.63)  < 0.001 6.6 0.360  
 Head and neck cancer 1 34 0.45 (0.20–1.01) 0.052 - -  
 Leukemia/lymphoma 2 224 1.17 (0.33–4.09) 0.809 85.7 0.008  
 Others 2 221 0.39 (0.24–0.65)  < 0.001 15.8 0.276  
CD9 detection method        0.015
 Flow cytometry 2 224 1.17 (0.33–4.09) 0.809 85.7 0.008  
 IHC 6 659 0.42 (0.30–0.60)  < 0.001 0.0 0.532  
 RT-PCR 3 258 0.30 (0.18–0.50)  < 0.001 0.0 0.993  
Publication year        0.060
 After 2005 4 444 0.74 (0.36–1.53) 0.417 79.6 0.002  
 Before 2005 7 697 0.33 (0.23–0.48)  < 0.001 0.0 0.708  
Race        0.804
 Asian 9 995 0.45 (0.26–0.78) 0.004 71.7  < 0.001  
 Caucasian 2 146 0.54 (0.32–0.91) 0.020 0.0 0.567  
Sample size        0.257
 Fewer than 110 5 400 0.37 (0.26–0.53)  < 0.001 0.0 0.875  
 More than 110 6 741 0.57 (0.28–1.18) 0.131 76.5 0.001  
  1. CI confidence interval, HR hazard ratio, IHC immunohistochemistry, RT-PCR reverse transcription-polymerase chain reaction